Biodexa Pharmaceuticals (BDRX) Prepaid Assets (2018 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Prepaid Assets of $441021.0 for Q4 2022, down 46.1% sequentially from $818242.4 in Q4 2021, and down 46.1% YoY from $818242.4 in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Prepaid Assets (2018 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Prepaid Assets for 5 years, with the latest figure at $441021.0 in Q4 2022.
- Quarterly Prepaid Assets fell 46.1% year-over-year to $441021.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $441021.0 (down 46.1% YoY) and the FY2022 annual result came in at $465341.0, down 44.28% from the prior year.
- Prepaid Assets eased to $441021.0 in Q4 2022 per BDRX's latest filing, from $818242.4 in the prior quarter.
- Over five years, Prepaid Assets peaked at $818242.4 in Q4 2021 and troughed at $178860.6 in Q4 2018.
- A 5-year average of $447345.6 and a median of $441021.0 in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2021 and 2022: Prepaid Assets surged 140.18% in 2021, then tumbled 46.1% in 2022.
- Over 5 years, Prepaid Assets stood at $178860.6 in 2018, then surged by 156.02% to $457927.3 in 2019, then slipped by 25.6% to $340676.4 in 2020, then soared by 140.18% to $818242.4 in 2021, then sank by 46.1% to $441021.0 in 2022.
- According to Business Quant data, Prepaid Assets over the past three periods registered $441021.0, $818242.4, and $340676.4 for Q4 2022, Q4 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 441,021.05 |
| Dec 31, 2021 | 818,242.44 |
| Dec 31, 2020 | 340,676.36 |
| Jun 30, 2019 | 457,927.29 |
| Dec 31, 2018 | 178,860.64 |